Zoetis Inc. (ZTS) Earnings Call Transcripts

Zoetis Inc.'s Latest Earnings Call - September 14, 2026

In the third quarter of 2026, Zoetis Inc. (ZTS:US) reported a revenue decline of 3% to 1%, significantly lower than the previously guided growth of 2% to 5%. The company attributed this downward revision to competitive pressures and a declining pet care market, which saw a 6.7% drop in visits. Management remains confident in their long-term growth potential, particularly through their innovation pipeline, but acknowledged the need for market stabilization before returning to sustainable growth rates.

Reported metrics

Guidance from management

Management maintained a cautious outlook, expecting operational revenue to decline by 3% to 1% for the remainder of the year, with a commitment to reassess guidance in November.

What management said

Sure. I've spent a lot of time coming in, getting up to speed on guidance, obviously, since there have been quite a few short-term dynamics here. And what I would say is we're confident in the guidance that we've shared. We made certain assumptions about the market no improvement in the market and things of that nature. The market is evolving as we expected. So we feel good about the guidance, and we look forward to ...

There's different -- and again, we have different strategy. I mean what's different, again, about parasiticide is we can target who -- where are we the primary. Obviously, that's not a [indiscernible] versus where. So it's a very different competitive market there where there's been some established players actually for a long time. And that's, as you know, been extremely competitive since the very beginning, paras -...

What analysts pressed on

Analysts expressed concerns about the sustainability of Zoetis' market share amid increasing competition and a declining pet care market. There were questions regarding the effectiveness of the pricing strategy and the timeline for market stabilization.

Main topics on the call

• Revenue Guidance Revision — Zoetis recalibrated its operational revenue guidance to negative 3% to negative 1%, down from a previous forecast of 2% to 5%. CEO Kristin Peck stated, "We saw a declining pet care market... this isn't us. This is the in...
• Competitive Pressures — The company faces intense competition in key categories, particularly in dermatology and parasiticide, with new entrants impacting market share. Peck noted, "We did get a third entrant overall in derm against Apoquel," i...
• Innovation Pipeline — Management highlighted a robust innovation pipeline, particularly in chronic kidney disease (CKD) and oncology, which they believe will drive future growth. Saccaro expressed excitement about the "value creation opportun...
• Market Dynamics — The overall pet care market is experiencing a slowdown, with wellness-related categories under pressure. Peck mentioned, "We're seeing where the highlights are is diagnostics... those customers are doing great," indicati...

Read the full Zoetis Inc. transcript (September 14, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 79 Zoetis Inc. earnings call transcripts on record, spanning January 15, 2020 to September 14, 2026. Based on this history, Zoetis Inc. reports quarterly. The most recent call on file is dated September 14, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

ZTS

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

79

First call

January 15, 2020

Most recent

September 14, 2026

Reporting cadence

quarterly